Baker Bros. Advisors Adds $7M in Eikon Therapeutics, Inc. ($EIKN)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors acquired a new position in Eikon Therapeutics, Inc. ($EIKN), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 555,555 shares of Eikon Therapeutics, Inc.. Baker Bros. Advisors's holdings in Eikon Therapeutics, Inc. were worth $7.25 million as of its most recent filing.
Eikon Therapeutics, Inc. Stock Up 18.9%
Shares of Eikon Therapeutics, Inc. ($EIKN) traded around $13.05 on Sunday, up 18.9% for the day.
Eikon Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
Get Eikon Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $EIKN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.